Molecular Pathology Laboratory
Understanding disease
                                One signal at a time....



Students' Material


Contact us
     TESTS OFFERED  Breast
 Colorectal cancer  Ewing's sarcoma Oligodendroglioma Cytogenetics    

Diagnostic Division


Personalized Precision
Genomic Medicine

We have invested heavily in state-of-the-art technologies to offer our patients "tailored" medical care. We believe that every patient is unique, therefore similar diseases can behave differently in different patients. The tests we apply to the diseased tissues allow us to administer treatment tailored to each patient. A concept known as individualized or personalized therapy.

  Fluorescent in situ
hybridization for Breast cancer
Breast cancer: This is the commonest cancer in woman. Amplification of Her-2/neu oncogene on chromosome 17 is associated with aggressive breast cancer. However, These cancers are amenable to treatment with monoclonal antibody to HER-2 protein receptor. The monoclonal antibody is known as Herceptin and is given to patients with breast cancer, who have amplified Her-2 oncogene.
We use FDA approved Metasystems to report on  the Her-2 gene status accurately within a week. Such quick and accurate reporting is important when time is so valuable.


Fluorescent in situ
hybridization for Ewing's sarcoma


Ewing's sarcoma: This is one of the most aggressive cancers and accurate diagnosis is vital. The chromosome 11:22 translocation if present helps in the differential diagnosis.






Genetic profiling of cancers and genetic disorders such as mental retardation.

We are currently using SNP 6.0 GeneChip from Affymetrix to do whole genome association studies and linkage analysis.

We are also testing and will shift to Cyto V2 Chips from Affymetrix to study copy number variations/LOH in colorectal cancer



  Fluorescent in situ
hybridization for bladder cancer
Urovision  a non-invasive highly sensitive test for the early detection of Bladder Cancer. The test is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21.